D-Y. Oh

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

D-Y. Oh, S-A Im, S.R. Park et al. · British Journal of Cancer · 2009 · 138 citations · Full text

Medicine, Oncology, Pharmacology +17

Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial

Yeon Hee Park, Tae‐Yong Kim, Gun Min Kim et al. · The Lancet Oncology · 2019 · 130 citations

Medicine, Oncology, Pharmacology +16

LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study

Narikazu Boku, M.-H. Ryu, D-Y. Oh et al. · Annals of Oncology · 2020 · 124 citations

Medicine, Oncology, Pharmacotherapy +15

High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer

Hanbo Min, Yoon Jun Kim, D-Y. Oh et al. · British Journal of Cancer · 2008 · 98 citations · Full text

Medicine, Oncology, Pathology +17

LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

Yelena Y. Janjigian, S-E. Al-Batran, Zev A. Wainberg et al. · Annals of Oncology · 2023 · 82 citations

Medicine, Oncology, Pharmacology +11